1. The Wheels on the Bus Go Round and Round
Just published in the June 2010 edition of the Journal of Drugs in Dermatology is a study comparing “Finacea in combination with Oracea” with “Metrogel in combination with Oracea”. Seeing this abstract published makes me want to let out a loud groan. So much of what we see as recently published rosacea research is just recycled sameness. The actual result of most …
2. Pyratine XR offers long term benefits
Always quick to generate a press release, Pyratine XR has been seen some recently published research, this time on the long term efficacy when treating mild to moderate rosacea. This latest research is in addition to the …
3. The Innovation of Natural Ingredients in Skin Care products
Are skin care products better for your skin, and less likely to be bad for rosacea sufferers, just because they contain natural ingredients ? Of course the answer to this seemingly simple question answer is not straight forward.
Regardless of the answer to this question, the interest in natural products to treat …
4. ROSIE: a new Rosacea Expert Group
With this recent abstract we learn about a new group of International Rosacea Experts.
Up until now the best known group of rosacea experts was organised by the National Rosacea Society, and was referred to as the Rosacea Expert Committee.
The NRS Expert Committee over the years has been responsible for amongst others the 4 following landmark rosacea publications;
Standard Classification of Rosacea
Standard Grading System …
5. NRS Blog highlights ocular demodex bacteria correlation
The NRS Blog has an article today which is an easy to read summary of some recent research into ocular symptoms and demodex mite bacteria. Mites and Eye Symptoms A new study has found there may be a link between ocular rosacea and bacteria associated with Demodex mites, microscopic inhabitants of normal skin that tend to …
6. Generic Oracea in First Quarter 2011 ?
A market analyst report just published speculates that Mylan Inc. may be in a position to market Generic Oracea as soon as the first quarter of 2011. These speculations are based on the successful outcome of a trial set down for December 2010 where Mylan will argue …
7. DRx AFC Medirepair (Arazine) now available in Japan
Signum Biosciences have announced that their first generation “Signal Transduction Modulator” product, AFC Medirepair (Arazine), is now officially available in Japan. From the product web site, the product has some other related products names such as Skin …
8. Vicept Therapeutics gets funding for V-101
News across the business web sites today a new company obtaining funding for a patent protected alpha-adrenergic receptor based treatment for the redness of rosacea.
Vicept Therapuetics is based in Malvern in Pennsylvania and is a privately held company.
From Fidelity Biosciences Joins $10M Series A for Vicept Therapeutics
“We are delighted by the strong investor interest in this round of financing which will allow us to …
